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Experimental details

Chemistry
All chemicals used were of reagent grade. Yields refer to purified products and are not optimized.
Melting points were determined in open capillaries on a Gallenkamp apparatus and are uncorrected.
Merck silica gel 60 (230-400 mesh) was used for column chromatography. Merck TLC plates, silica gel 60 F 254 were used for TLC. 1 μL/min. The purity of monovalent (7a-e) and bivalent (8a,b) ligands was assessed by RP-HPLC and was found to be higher than 95%. An Agilent 1100 Series system equipped with a Zorbax Eclipse XDB-C8 (4.6 x 150 mm, 5 m) column was used in the HPLC analysis with methanol-(1% acetic acid-water) (50:50) as the mobile phase at a flow rate of 0.5 mL/min. UV detection was achieved at 254 nm.
2-[4-[(4-Nitrophenoxy)carbonylamino]piperidin-1-yl]ethyl 4-Amino-5-chloro-2-methoxybenzoate (10).
A solution of compound 7a 1 (0.93 g, 2.17 mmol) in TFA (10 mL) was stirred at room temperature for 10 min. The excess of TFA was removed under reduced pressure by azeotropic distillation with toluene and the residue obtained was partitioned between ethyl acetate and a saturated solution of sodium carbonate. The organic layer was washed with water, dried over sodium sulfate, and evaporated under reduced pressure. The resulting residue (0.63 g, 1.92 mmol) was dissolved in chloroform (20 mL) and bis (4-nitrophenyl) carbonate (0.59 g, 1.94 mmol) was added. The reaction mixture was stirred at room 6 temperature for 4 days and then concentrated under reduced pressure. The residue was diluted with dichloromethane and washed with a saturated solution of sodium carbonate. The organic layer was dried over sodium sulfate and evaporated under reduced pressure. The residue was purified by flash chromatography with dichloromethane-methanol (9:1) as the eluent to give compound 10 as a yellow solid (0.59 g, yield 55%, mp 145-147° C). 1 A mixture of compound 12 (60 mg, 0.136 mmol) in TFA was stirred at room temperature for 10 min.
The excess of TFA was removed under reduced pressure by azeotropic distillation with toluene and the residue was dissolved into chloroform (15 mL). Compound 10 (65 mg, 0.13 mmol) and TEA (0.5 mL)
were added to the resulting solution and the reaction mixture was stirred at room temperature for 18 h. 
15-13 C-1-[1-[2-(4-Amino-5-chloro-2-methoxybenzoyloxy)ethyl]piperidin-4-ylamino]-1,12-dioxo-
5,8-dioxa-2,11,13-triazapentadecan-15-oic acid (7d).
A mixture of compound 7c (55 mg, 0.079 mmol) in ethanol (20 mL) containing 10% Pd/C (10 mg) was hydrogenated at atmospheric pressure and room temperature for 3 h. The catalyst was then filtered off and the filtrate was concentrated under reduced pressure. The residue was purified by washing with chloroform to give acid 7d as a yellow oil (40 mg, yield 84%). 1 46.2, 50.1, 52.4, 55.7, 56.4, 61.8, 69.4, 69.7, 69.8, 69.9, 70.0, 70.3, 97.9, 107.0, 108.0, 132.5, 150.1 
Bivalent ligand 8b.
In a microwave tube, a solution of 13 (25 mg, 0.081 mmol) in DMF (5.0 mL) containing 7e (190 mg, 0.24 mmol), CuBr (5.7 mg, 0.040 mmol), and DIPEA (7.0 µL, 0.040 mmol) was exposed to microwave irradiation in a CEM Discover instrument for 50 min (5 x 10 min, T = 60 °C, W = 150) and finally evaporated under reduced pressure. The residue was dissolved with water (15 mL) and 33% NH 4 OH (4.0 mL). The aqueous solution was extracted with dichloromethane and the organic layer was dried over sodium sulfate and concentrated under reduced pressure. The resulting residue was purified by washing with ethyl acetate to give dimer 8b as a yellow oil (51 mg, yield 33%). 1 
Tetravalent ligand 9.
In a microwave tube, a solution of 14 (27 mg, 0.042 mmol) in DMF (5.0 mL) containing 7e (190 mg, 0.24 mmol), CuBr (11 mg, 0.077 mmol), and DIPEA (14 µL, 0.084 mmol) was exposed to microwave irradiation in a CEM Discover instrument for 50 min (5 x 10 min, T = 60 °C, W = 150) and finally evaporated under reduced pressure. The residue was dissolved with water (15 mL) and 33% NH 4 OH (4.0 mL). The aqueous solution was extracted with dichloromethane and the organic layer was dried over sodium sulfate and concentrated under reduced pressure. The resulting residue was purified by washing with ethyl acetate to give tetravalent ligand 9 as a yellow oil (55 mg, yield 34%). 1 37 (m, 12H), 3.44-3.51 (m, 112H), 3.70 (s, 12H), 3.77 (t, J = 5.1, 8H), 4.14-4.21 (m, 16H) 
Binding assays
Male Dunkin-Hartley guinea pigs (Charles River Italia, Calco, CO, Italy) weighing 300-400 g were 
BRET recording of 5-HT 4 R-G protein coupling
The preparation of retroviral vectors coding for Rluc-tagged human 5-HT 4 receptor and RGFP-fused to Gβ 1 , and the transduction of SH-5YSY human neuroblastoma cells were done using procedures described previously. 5 The 5-HT 4 R-Rluc fusion protein cDNA was engineered by replacing the stop codon of the receptor with a sequence encoding a 13-mer linker peptide (RTEEQKLISEEDL) and cloning it in frame with the Rluc sequence into the retroviral expression vector pQIXN (Clontech). Cells were grown in a 1:1 mixture of Dulbecco's modified Eagle's medium and F-12, with 10% (v/v) fetal calf serum, 100 μg/mL hygromycin B and 400 μg/mL G418 in a humidified atmosphere of 5% CO 2 at 37 °C. Enriched membranes from transfected cells were obtained by differential centrifugation 5 and stored in aliquots at -80 °C before use. Receptor/Gβ 1 interactions were measured in membrane preparations (5 μg of proteins in a total volume of 100 μL phosphate-buffered saline) placed into white plastic 96-well plates (Packard Opti-plate); BRET recording and computations methods were described previously. 5 The ligand concentration yielding 50% inhibition of coupling (IC 50 ) were computed from concentration-inhibition curves obtained using 8 log-spaced concentrations of the ligands in the presence of 100 nM serotonin. The data were analyzed by nonlinear curve fitting with a general 4-parametrs logistic function. 5 
cAMP measurements
GloSensor-22F 6 expressing 2B2 cell lines were generated by infecting the cells with a selfinactivating viral construct prepared after subcloning into the retroviral expression vector pQCIXN (Clontech Laboratories, Inc) the biosensor sequence excised from the GloSensor 22F plasmid (Promega, USA). Virally transduced cells were cloned and selected for neomycin resistance; the best biosensor expressing clone was then chosen after screening for forskolin responsiveness of luminescence signals.
The selected cell line was further transduced with viral constructs encoding Gαs and human 5-HT 4 R as described above for the BRET assay. To measure cAMP responsiveness of the compounds, cells were seeded in 96-well white-opaque plates at a density of 25 x 10 3 cells/well 24 h before the experiment.
Two hours before the assay, cells were washed once with PBS, and further incubated 105 minutes in PBS containing 25 mM glucose and 2 mM luciferin in a total volume of 60 μL. Assay was started by addition of varying concentrations (up to 10 M) of ligands and 1 mM (final) IBMX in a total volume of 100 μL/well. Luminescence form each well was then counted every 30s with an integration time of 0.5s for up to 60 minutes using a plate luminometr (Victoe EnLight, Perkin Elmer). cAMP response was determined as peak luminescence, area under the 60 min luminescence-time curves, or the initial rate of luminescence increase. All three methods gave similar results.
